1st Apr 2016 15:33
GlaxoSmithKline plc
Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons
In accordance with Disclosure and Transparency Rule 3.1.4R(1)(a), I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares ('ADSs') of GlaxoSmithKline plc (the 'Company').
On 31 March 2016, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £14.05 per Ordinary Share, and notional ADSs at a price of $40.53 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2016 to 31 March 2016:
Non Executive Director | Ordinary Shares | No. of ADSs | |
Sir Philip Hampton | 3,113.879 |
| |
Professor Sir Roy Anderson | 511.566 |
| |
Vindi Banga | 1,512.456 |
| |
Dr Stephanie Burns | 678.178 |
| |
Stacey Cartwright | 378.114 |
| |
Lynn Elsenhans | 1,389.096 |
| |
Judy Lewent | 526.173 |
| |
Sir Deryck Maughan | 1,356.357 |
| |
Dr Daniel Podolsky | 1,227.736 |
| |
Urs Rohner | 467.082 |
| |
Hans Wijers | 378.114 |
| |
Jesse Goodman was appointed to the Board with effect from 1 January 2016.
In accordance with the share allocation arrangements for Non-Executive Directors, 25% of Jesse Goodman's fees will be retained and will be reinvested in the Company's ADSs at a future date, to be mutually agreed.
The Company and the Non-Executive Directors were advised of these allocations on 1 April 2016.
V A Whyte
Company Secretary
1 April 2016
Related Shares:
Glaxosmithkline